Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
11.92
+1.06 (9.76%)
At close: Sep 26, 2025, 4:00 PM EDT
11.42
-0.50 (-4.19%)
After-hours: Sep 26, 2025, 7:33 PM EDT
Contineum Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Contineum Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $22.2, which forecasts a 86.24% increase in the stock price over the next year. The lowest target is $16 and the highest is $31.
Price Target: $22.2 (+86.24%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Contineum Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $20 | Buy | Initiates | $20 | +67.79% | Sep 25, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $21 | Buy | Maintains | $20 → $21 | +76.17% | Aug 18, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $25 → $20 | Buy | Maintains | $25 → $20 | +67.79% | May 19, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $31 | Buy | Reiterates | $31 | +160.07% | May 15, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +92.95% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.52
from -2.18
EPS Next Year
-2.76
from -2.52
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.88 | -1.50 | |
| Avg | -2.52 | -2.76 | |
| Low | -2.68 | -3.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.